Brief: Corvus Pharmaceuticals Presents New Interim Soquelitinib Data From Its Phase 1/1B T Cell Lymphoma Trial
09/12/2023 23:57
Dec 9 (Reuters) - Corvus Pharmaceuticals Inc CRVS.O :
* CORVUS PHARMACEUTICALS PRESENTS NEW INTERIM SOQUELITINIB
DATA
FROM ITS PHASE 1/1B T CELL LYMPHOMA TRIAL
* CORVUS PHARMACEUTICALS INC - RESULTS CONFIRMED PATIENT
ELIGIBILITY REQUIREMENTS AND ENDPOINTS PLANNED FOR SOQUELITINIB
PHASE 3 CLINICAL TRIAL IN PTCL
Source text for Eikon: ID:nGNX9CD8n3
Further company coverage: CRVS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Corvus Pharmaceuticals
See all newsBrief: Corvus Pharmaceuticals Announces Initiation Of Phase 1B Clinical Trial Of Soquelitinib For Patients With Hidradenitis Suppurativa
Corvus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Toll Brothers, TG Therapeutics, CECO Environmental